<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579914</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1301102</org_study_id>
    <nct_id>NCT03579914</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Metoprolol Combining RIPC on Myocardial Protection in STEMI Patients</brief_title>
  <official_title>Effect of Intravenous Metoprolol Combining RIPC on Myocardial Protection in Anterior ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary PCI-A Prospective,Multicenter,Random Control,Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aim to discover the difference of protective effect on comparing Metoprolol
      administration before cardiac reperfusion combined with remote ischemic post-conditioning
      (RIPC) in patients with anterior STEMI in China. This study sought to find possible strategy
      on ameliorate the patients with anterior STEMI in China through the mechanisms on cardiac
      protection before cardiac reperfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter randomized controlled clinical trial, and planning to enroll 1200
      patients with anterior STEMI. At the first medical contact，patients who meet the
      inclusion/exclusion criteria are divided into different groups before reperfusion. Patients
      randomize into placbo, Metoprolol, RIPC and Metorolol+RIPC groups. Subsequently, the
      investigator conduct diagnosis and treatment according to the patient's specific conditions.
      It is important to test early markers of myocardial damage at 12hrs, 24hrs, 36hrs, 48hrs and
      60hrs(must item)during hospitalization. If the patient is treated with PCI, immediate
      post-operative myocardial injury markers are required(must item). Meanwhile, the investigator
      will collect information about disease diagnosis and treatment. All patients were followed
      for 1 year with an office visit at 1,3,6,9 and 12 months or a telephone call to evaluate the
      Health status and clinical events of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size</measure>
    <time_frame>60 hours</time_frame>
    <description>Estimating myocardial infarct size by area under CK, CK-MB curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarct size measured by MRI</measure>
    <time_frame>7 days after AMI</time_frame>
    <description>myocardial infarct size measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital heart failure</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Incidence of in-hospital heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>MACCE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bradycardia and low pressue</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of bradycardia and low pressue</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Anterior Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive intravenous placebo injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous metoprolol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive intravenous metoprolol injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive RIPC treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous metoprolol and RIPC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive intravenous metoprolol injection and RIPC treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous Placebo</intervention_name>
    <description>Patients receive intravenous Placebo injection</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Injectable Product</intervention_name>
    <description>Patients receive intravenous Metoprolol injection</description>
    <arm_group_label>Intravenous metoprolol and RIPC group</arm_group_label>
    <arm_group_label>Intravenous metoprolol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Romote Ischemic Post-Conditioning (RIPC)</intervention_name>
    <description>Patients receive RIPC treatment</description>
    <arm_group_label>Intravenous metoprolol and RIPC group</arm_group_label>
    <arm_group_label>RIPC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ages 18 to 80 years, presenting within 6 h of symptoms onset, with anterior
             STEMI, de novo occlusion of LAD (TIMI [Thrombolysis In Myocardial Infarction] flow
             grade 0 to 1), and planned pPCI were eligible. Anterior STEMI was defined as the
             occurrence of &gt;20 min of chest pain and ST-segment elevation (&gt;2 mm) in at least 2
             contiguous precordial leads.

        Exclusion Criteria:

        - previous anterior STEMI or ＜6 months nonanterior STEMI; Killip class IV; evidence of
        retrograde filling by collaterals at coronary angiography; severe multivessel coronary
        artery disease likely to require further interventions before follow-up ce-CMR (4 months);
        known severe abdominal aortic aneurysm (&gt;50 mm); or severe peripheral artery disease (class
        III to IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing An Zhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunmei Wang</last_name>
      <phone>+8613521901670</phone>
      <email>wangchunmei0214@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Univerisity People'Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weimin Wang</last_name>
      <phone>+8613901366076</phone>
      <email>weiminwang@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lefeng Wang</last_name>
      <phone>+8613601255020</phone>
      <email>wlf311@sohu.com</email>
    </contact>
    <contact_backup>
      <phone>+8613601255020</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guangdong general hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Tan</last_name>
      <phone>+8613903073651</phone>
      <email>tanning100@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinshun Gu</last_name>
      <phone>+8613930139688</phone>
      <email>348220248@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
      <phone>+8613704673319</phone>
      <email>huilee_2006@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhengzhou medical university</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Li</last_name>
      <phone>+8613607641631</phone>
      <email>liling63035@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genshan Ma</last_name>
      <phone>+8613002580569</phone>
      <email>magenshan@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqing Wu</last_name>
      <phone>+8613870885171</phone>
      <email>wuyanqing01@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Liu</last_name>
      <phone>+8613500810268</phone>
      <email>liubin3333@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the second affiliated hospital of Dalian medical university</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Qu</last_name>
      <phone>+8613304261697</phone>
      <email>qupeng777@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenyang military district general hospital of the people's liberation army</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Wang</last_name>
      <phone>+8615309882359</phone>
      <email>wangbindl@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of military medical university</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhijing Zhao</last_name>
      <phone>+8613772020951</phone>
      <email>zhaozhj@fmmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Jin</last_name>
      <phone>+8613272605717</phone>
      <email>jjxqyy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunjie Li</last_name>
      <phone>+8613820600988</phone>
      <email>ykwn@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjuan Zhang</last_name>
      <phone>+8613002226922</phone>
      <email>zwzzyy2013@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yining Yang</last_name>
      <phone>+8613199860611</phone>
      <email>yangyn5126@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>July 5, 2018</last_update_submitted>
  <last_update_submitted_qc>July 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <keyword>Anterior Myocardial Infarction</keyword>
  <keyword>Intravenous Metoprolol</keyword>
  <keyword>RIPC</keyword>
  <keyword>Myocardial Protection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

